2019 Peripheral T-Cell Lymphomas (PTCL) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

April 2019 | 211 pages | ID: 2B23B0E11B0EN
VPAResearch

Abstracts

The global clinical trial report- “2019 Peripheral T-Cell Lymphomas (PTCL) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Peripheral T-Cell Lymphomas (PTCL). It presents in-depth analysis of Peripheral T-Cell Lymphomas (PTCL) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Peripheral T-Cell Lymphomas (PTCL).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Peripheral T-Cell Lymphomas (PTCL) clinical trials by-

• Current Trial Status
• Type of the trial
• Sponsor Type
• Enrollment Trends
• Region
• Countries
• Trial Phase

The report also identifies the potential drug candidates under development for treatment of Peripheral T-Cell Lymphomas (PTCL)

The research work is prepared through extensive and continuous research on Peripheral T-Cell Lymphomas (PTCL) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:

• All major trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Peripheral T-Cell Lymphomas (PTCL) patients are identified
• The report includes panorama of Peripheral T-Cell Lymphomas (PTCL) clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Peripheral T-Cell Lymphomas (PTCL) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Peripheral T-Cell Lymphomas (PTCL) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
  2.2.1 Peripheral T-Cell Lymphomas (PTCL) Clinical Trials by Region
  2.2.2 Average Enrollment of Peripheral T-Cell Lymphomas (PTCL) Clinical Trials
  2.2.3 Companies participating in Trials
  2.2.4 Drugs under Study for Peripheral T-Cell Lymphomas (PTCL) Treatment, 2019

3. REGION WISE PERIPHERAL T-CELL LYMPHOMAS (PTCL) CLINICAL TRIALS

3.1 Asia Pacific Peripheral T-Cell Lymphomas (PTCL) Clinical Trials by Country
3.2 Europe Peripheral T-Cell Lymphomas (PTCL) Clinical Trials by Country
3.3 North America Peripheral T-Cell Lymphomas (PTCL) Clinical Trials by Country
3.4 Middle East and Africa Peripheral T-Cell Lymphomas (PTCL) Clinical Trials by Country
3.5 South and Central America Peripheral T-Cell Lymphomas (PTCL) Clinical Trials by Country

4. PERIPHERAL T-CELL LYMPHOMAS (PTCL) CLINICAL TRIAL TRENDS

4.1 Start Year wise Peripheral T-Cell Lymphomas (PTCL) Clinical Trials
4.2 Phase wise Peripheral T-Cell Lymphomas (PTCL) Clinical Trials
4.3 Trial Status wise Peripheral T-Cell Lymphomas (PTCL) Clinical Trials
4.4 Trial Type wise Peripheral T-Cell Lymphomas (PTCL) Clinical Trials

5. PERIPHERAL T-CELL LYMPHOMAS (PTCL) AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Peripheral T-Cell Lymphomas (PTCL) Trials by Year
5.2 Average Enrollment in Peripheral T-Cell Lymphomas (PTCL) Trials by Phase
5.3 Average Enrollment in Peripheral T-Cell Lymphomas (PTCL) Trials by Status
5.4 Average Enrollment in Peripheral T-Cell Lymphomas (PTCL) Trials by Type of Trial

6. COMPANIES PARTICIPATING IN PERIPHERAL T-CELL LYMPHOMAS (PTCL) CLINICAL TRIALS

6.1 Peripheral T-Cell Lymphomas (PTCL) Trials by Sponsor Type
6.2 Peripheral T-Cell Lymphomas (PTCL) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Peripheral T-Cell Lymphomas (PTCL) Trials- Phase
7.2 Peripheral T-Cell Lymphomas (PTCL) Trials- Phase
7.3 Peripheral T-Cell Lymphomas (PTCL) Trials- Phase
7.4 Peripheral T-Cell Lymphomas (PTCL) Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Peripheral T-Cell Lymphomas (PTCL) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Peripheral T-Cell Lymphomas (PTCL) Clinical Trials and Enrolment
Figure 5: Europe – Country wise Peripheral T-Cell Lymphomas (PTCL) Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Peripheral T-Cell Lymphomas (PTCL) Clinical Trials and Enrolment
Figure 7: North America – Country wise Peripheral T-Cell Lymphomas (PTCL) Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Peripheral T-Cell Lymphomas (PTCL) Clinical Trials and Enrolment
Figure 9: Peripheral T-Cell Lymphomas (PTCL) Clinical Trials by Phase
Figure 10: Peripheral T-Cell Lymphomas (PTCL) Clinical Trials by Trial Status
Figure 11: Peripheral T-Cell Lymphomas (PTCL) Clinical Trials by Type
Figure 12: Peripheral T-Cell Lymphomas (PTCL) Clinical Trials by Sponsor Type
Figure 13: Peripheral T-Cell Lymphomas (PTCL) Clinical Trials by Leading Sponsors
Figure 14: Peripheral T-Cell Lymphomas (PTCL) Average Enrollment by Phase
Figure 15: Peripheral T-Cell Lymphomas (PTCL) Average Enrollment by Trial Status
Figure 16: Peripheral T-Cell Lymphomas (PTCL) Average Enrollment by Type
Figure 17: Peripheral T-Cell Lymphomas (PTCL)- Average Enrolment by Type of Sponsors
Figure 18: Peripheral T-Cell Lymphomas (PTCL)- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Peripheral T-Cell Lymphomas (PTCL) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Peripheral T-Cell Lymphomas (PTCL) Clinical Trials and Enrolment
Table 5: Europe – Country wise Peripheral T-Cell Lymphomas (PTCL) Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Peripheral T-Cell Lymphomas (PTCL) Clinical Trials and Enrolment
Table 7: North America – Country wise Peripheral T-Cell Lymphomas (PTCL) Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Peripheral T-Cell Lymphomas (PTCL) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Peripheral T-Cell Lymphomas (PTCL) Average Enrollment by Phase
Table 15: Peripheral T-Cell Lymphomas (PTCL) Average Enrollment by Trial Status
Table 16: Peripheral T-Cell Lymphomas (PTCL) Average Enrollment by Type
Table 17: Peripheral T-Cell Lymphomas (PTCL)- Average Enrolment by Type of Sponsors
Table 18: Peripheral T-Cell Lymphomas (PTCL)- Enrolment by Leading Sponsors